Warner Chilcott, Lupin Settle Birth Control IP Dispute
Under the deal, Lupin has agreed not to launch generic Loestrin before July 22, 2014, unless another drugmaker enters the market sooner. If Lupin then launches its product, Warner Chilcott can sue, the companies said Thursday.
Warner Chilcott has also granted Lupin a nonexclusive license for Femcon, which would allow Lupin to sell an authorized...
To view the full article, register now.